Biological agents in monotherapy for the treatment of rheumatoid arthritis

Gabay, Cem and Hasler, Paul and Kyburz, Diego and Soukas, Alexander and Villiger, Peter M. and von Kempis, Johannes and Walker, Ulrich A.. (2014) Biological agents in monotherapy for the treatment of rheumatoid arthritis. Swiss Medical Weekly, 144. w13950.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/62302/

Downloads: Statistics Overview


Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease, which results in joint destruction and permanent disability. The advent of disease-modifying antirheumatic drugs (DMARDs) has made a profound impact on the outcome and prognosis of RA. Methotrexate (MTX) is a central agent in RA therapy, and is used either alone or in combination with biological DMARDs. However, a large proportion of RA patients (20%-40%) either do not respond to or are unable to tolerate MTX or the alternative agents used in place of MTX (including leflunomide, sulfasalazine, azathioprine, hydroxycholoquine and combination DMARDs). For these patients, monotherapy with biological DMARDs is a key treatment option that balances tolerability with improved clinical outcomes. This article reviews the data for four biological agents approved for use as monotherapy in Switzerland (adalimumab, certolizumab pegol, etanercept and tocilizumab) in order to formulate a consensus statement on their roles in biologic monotherapy of RA.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Rheumatology (Kyburz)
UniBasel Contributors:Kyburz, Diego
Item Type:Article, refereed
Article Subtype:Further Journal Contribution
Publisher:EMH Schweizerischer Arzteverlag
Note:Publication type according to Uni Basel Research Database: Journal item
Identification Number:
Last Modified:29 Jul 2020 15:55
Deposited On:29 Jul 2020 15:55

Repository Staff Only: item control page